Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

merck sharp & dohme corp. - fosaprepitant (dimeglumina) - fosaprepitant (dimeglumina)....150 mg

United States - English - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use - fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co., inc.'s emend (fosaprepitant) for injection. however, due to merck sharp & dohme corp., a subsidiary of merck & co., inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. fosaprepitant for injection is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

257.6 mg of fosaprepitant demiglumine is equivalent to 157.5 mg of fosaprepitant free acid -

United States - English - NLM (National Library of Medicine)

spes pharmaceuticals inc. - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - focinvez, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use  - focinvez has not been studied for treatment of established nausea and vomiting. focinvez is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported [see warnings and precautions (5.2), and adverse reactions ( 6.2)] . - taking pimozide. inhibition of cyp3a4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a cyp3a4 substrate, potentially c

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. - fosaprepitant (fosaprepitant dimeglumine) - powder lyophilized for solution for infusion - 150mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. - fosaprepitant (fosaprepitant dimeglumine) - powder lyophilized for solution for infusion - 150mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - solution - 150,0 mg - each vial contains fosaprepitant dimeglumine equivaleng to fosaprepitant 150,0 mg

United States - English - NLM (National Library of Medicine)

truemed group llc - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) -